Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib as Adjuvant Therapy After TACE in HCC
CTR20131510Phase 3Suspended
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brivanib in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Nov 2013; status: suspended.
02
Drugs
brivanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20131510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131510.